Concepedia

Publication | Open Access

Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway

DOIFull Paper Access

65

Citations

30

References

2019

Year

Maria M. Rubinstein, David M. Hyman, Imogen Caird, Helen Won, Krysten Soldan, Kenneth Seier, Alexia Iasonos, William P. Tew, Roisin E. O’Cearbhaill, Rachel N. Grisham,
Cancer

Abstract

In patients with heavily pretreated advanced endometrial cancer prospectively selected for tumors with activating PI3K pathway mutations, LY3023414 demonstrated modest single-agent activity and a manageable safety profile.

References

YearCitations

Page 1